Pear Therapeutics has developed THRIVETM, a mobile medical application to be used in conjunction with medication for treating schizophrenia
Medication Plus Patient-Facing Smartphone Application
Clinician-Facing Web Interface
THRIVETM enhances the efficacy of atypical anti-psychotics for schizophrenia
A 30-day trial of THRIVETM shows significant reduction in the following:
In a real world usability study, 342 patients with schizoaffective disorders were given THRIVE for 6 months following hospitalization.
The study demonstrated robust usage and engagement suggesting that THRIVETM could be an efficacious, long-lived therapeutic intervention.
*THRIVETM is not yet available for sale in the United States